All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-09-21T10:46:54.000Z

What were your highlights from EHA 2023?

Sep 21, 2023
Share:

During the European Hematology Association (EHA) 2023 Hybrid Congress, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New York, US. We asked: What were your highlights from EHA 2023?

What were your highlights from EHA 2023?

Roboz begins by summarizing the application of targeted agents to traditional chemotherapy regimens, and how the use of the FLT3 inhibitor midostaurin in the RATIFY trial has paved the way in changing the treatment landscape. Roboz goes on to review the use of gilteritinib in the MORPHO trial, which evaluated maintenance gilteritinib after allogeneic stem cell transplant in patients with FLT3-ITD (internal tandem duplication)–positive acute myeloid leukemia (AML). Roboz also touches on how patients who are measurable residual disease (MRD)-positive have been responding to gilteritinib and the importance of MRD monitoring in patients with FLT3 mutations. Roboz then highlights the need to target the NPM1 mutation in patients with AML, based on late-breaking data gathered from the KOMET-001 trial, where patients with NPM1-mutant relapsed or refractory acute AML have been treated with the Menin inhibitor ziftomenib. Roboz rounds off by mentioning the importance of combining ziftomenib with current upfront therapies to try and prevent relapsed AML.

Newsletter

Subscribe to get the best content related to AML delivered to your inbox